INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA

PHOENIX, Sept. 29, 2017 (GLOBE NEWSWIRE) -- In advancing its pipeline of innovative medicines, INSYS Therapeutics, Inc. (NASDAQ:INSY) ( “INSYS” or “the company”), announced today that it filed a New Drug Application (NDA) for a novel...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news